AI Engines For more Details: Perplexity Kagi Labs You
Bacterial Infections in Animals: Sarafloxacin is primarily used in veterinary medicine to treat bacterial infections in animals. It is effective against a wide range of susceptible bacterial pathogens, including those causing respiratory infections, gastrointestinal infections, urinary tract infections, and skin infections in animals.
Respiratory Infections: Sarafloxacin may be used to treat respiratory infections in animals, including pneumonia and bronchitis caused by susceptible bacteria.
Gastrointestinal Infections: Sarafloxacin may be prescribed to treat gastrointestinal infections in animals, such as bacterial gastroenteritis and enteric infections caused by susceptible pathogens.
Urinary Tract Infections: Sarafloxacin may be effective in treating urinary tract infections in animals caused by susceptible bacteria. It can help alleviate symptoms such as urinary frequency, urgency, and discomfort.
Skin and Soft Tissue Infections: Sarafloxacin may be used to treat skin and soft tissue infections in animals, including wounds, abscesses, and dermatitis caused by susceptible bacteria.
Aquatic Animal Infections: Sarafloxacin may also be used to treat bacterial infections in aquatic animals, including fish and aquatic reptiles.
Veterinary Prescription: Sarafloxacin is a prescription medication and should only be used in animals under the supervision of a veterinarian. Proper diagnosis of the bacterial infection and determination of the susceptibility of the pathogen to sarafloxacin are essential before initiating treatment.
Adverse Effects: As with all antibiotics, sarafloxacin may cause adverse effects in animals, including gastrointestinal upset, allergic reactions, and rare but serious adverse events such as tendon rupture and central nervous system effects.
Resistance Development: The use of sarafloxacin in animals can contribute to the development of antibiotic resistance in bacterial populations. Therefore, its use should be judicious and based on susceptibility testing whenever possible to minimize the risk of resistance emergence.
Regulatory Status: The use of sarafloxacin in food-producing animals is regulated by veterinary authorities in many countries to ensure the safety of food products derived from treated animals and to minimize the risk of antibiotic resistance transmission to humans.
Rank | Probiotic | Impact |
---|---|---|
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
Acne | 0.5 | -0.5 | |
ADHD | 7.5 | 1 | 6.5 |
Age-Related Macular Degeneration and Glaucoma | 1 | 0.5 | 1 |
Allergic Rhinitis (Hay Fever) | 3 | 2.5 | 0.2 |
Allergies | 7.5 | 3.5 | 1.14 |
Allergy to milk products | 2.5 | 1.5 | 0.67 |
Alopecia (Hair Loss) | 2.5 | 2.5 | |
Alzheimer's disease | 6 | 10 | -0.67 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.5 | 1.5 | 2 |
Ankylosing spondylitis | 6.5 | 3 | 1.17 |
Anorexia Nervosa | 0.5 | 3.5 | -6 |
Antiphospholipid syndrome (APS) | 3.5 | 0.5 | 6 |
Asthma | 2 | 1 | 1 |
Atherosclerosis | 2 | 3 | -0.5 |
Atrial fibrillation | 5.5 | 3.5 | 0.57 |
Autism | 15 | 14 | 0.07 |
Barrett esophagus cancer | 1 | 0.5 | 1 |
benign prostatic hyperplasia | 0.5 | 0.5 | |
Bipolar Disorder | 2.5 | 2.5 | 0 |
Brain Trauma | 1 | 1 | 0 |
Carcinoma | 6 | 4 | 0.5 |
Celiac Disease | 4 | 6 | -0.5 |
Cerebral Palsy | 2 | 2 | 0 |
Chronic Fatigue Syndrome | 9 | 10 | -0.11 |
Chronic Kidney Disease | 4 | 3 | 0.33 |
Chronic Lyme | 1 | -1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 3.5 | 1.5 | 1.33 |
Chronic Urticaria (Hives) | 3 | 2 | 0.5 |
Coagulation / Micro clot triggering bacteria | 2.5 | 2 | 0.25 |
Colorectal Cancer | 8 | 1.5 | 4.33 |
Constipation | 2.5 | 1 | 1.5 |
Coronary artery disease | 2.5 | 1.5 | 0.67 |
COVID-19 | 18 | 21.5 | -0.19 |
Crohn's Disease | 13 | 9 | 0.44 |
cystic fibrosis | 1.5 | 1.5 | 0 |
deep vein thrombosis | 1.5 | 1.5 | 0 |
Depression | 16 | 12.5 | 0.28 |
Dermatomyositis | 0.5 | 0.5 | 0 |
Eczema | 2 | 3.5 | -0.75 |
Endometriosis | 5 | 2 | 1.5 |
Eosinophilic Esophagitis | 0.5 | 0.5 | 0 |
Epilepsy | 4.5 | 3 | 0.5 |
Fibromyalgia | 4.5 | 4.5 | 0 |
Functional constipation / chronic idiopathic constipation | 9.5 | 6.5 | 0.46 |
gallstone disease (gsd) | 3.5 | 1.5 | 1.33 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 3 | 1.5 | 1 |
Generalized anxiety disorder | 3.5 | 3 | 0.17 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.5 | -0.5 | |
Gout | 0.5 | -0.5 | |
Graves' disease | 2 | 2 | 0 |
Halitosis | 1.5 | 0.5 | 2 |
Hashimoto's thyroiditis | 3.5 | 1.5 | 1.33 |
Hidradenitis Suppurativa | 1.5 | 0.5 | 2 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 5.5 | 1.5 | 2.67 |
hypercholesterolemia (High Cholesterol) | 1 | 1 | |
hyperglycemia | 0.5 | 2 | -3 |
Hyperlipidemia (High Blood Fats) | 1 | 0.5 | 1 |
hypersomnia | 1 | -1 | |
hypertension (High Blood Pressure | 3.5 | 7.5 | -1.14 |
Hypothyroidism | 2 | -2 | |
Hypoxia | 1 | 1 | |
IgA nephropathy (IgAN) | 7 | -7 | |
Inflammatory Bowel Disease | 8 | 12.5 | -0.56 |
Insomnia | 1.5 | 1.5 | 0 |
Intelligence | 2 | 1 | 1 |
Intracranial aneurysms | 2 | 0.5 | 3 |
Irritable Bowel Syndrome | 6.5 | 6 | 0.08 |
Liver Cirrhosis | 7.5 | 5 | 0.5 |
Long COVID | 13.5 | 14 | -0.04 |
Low bone mineral density | 1.5 | -1.5 | |
Lung Cancer | 1.5 | 1.5 | 0 |
ME/CFS with IBS | 2 | 4 | -1 |
ME/CFS without IBS | 3.5 | 3.5 | 0 |
Menopause | 3 | 3 | |
Metabolic Syndrome | 13 | 12.8 | 0.02 |
Mood Disorders | 20 | 13 | 0.54 |
multiple chemical sensitivity [MCS] | 2 | 0.5 | 3 |
Multiple Sclerosis | 8.5 | 9 | -0.06 |
Multiple system atrophy (MSA) | 2 | 1.5 | 0.33 |
Neuropathy (all types) | 1 | 0.5 | 1 |
neuropsychiatric disorders (PANDAS, PANS) | 1.5 | 1.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4 | 7.5 | -0.88 |
NonCeliac Gluten Sensitivity | 0.5 | -0.5 | |
Obesity | 13.5 | 7 | 0.93 |
obsessive-compulsive disorder | 11 | 6.5 | 0.69 |
Osteoarthritis | 4 | 0.5 | 7 |
Osteoporosis | 3 | 1 | 2 |
pancreatic cancer | 1 | 1 | |
Parkinson's Disease | 4.5 | 7 | -0.56 |
Polycystic ovary syndrome | 4 | 3 | 0.33 |
Postural orthostatic tachycardia syndrome | 0.5 | 1 | -1 |
Premenstrual dysphoric disorder | 1.5 | 0.5 | 2 |
primary biliary cholangitis | 0.5 | 1.5 | -2 |
Psoriasis | 7 | 4 | 0.75 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 11 | 6 | 0.83 |
Rosacea | 2 | 1 | 1 |
Schizophrenia | 10.5 | 3 | 2.5 |
scoliosis | 0.5 | 2 | -3 |
Sjögren syndrome | 5 | 5 | 0 |
Sleep Apnea | 2.5 | 2.5 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 2 | 1 | 1 |
Stress / posttraumatic stress disorder | 4.5 | 3.5 | 0.29 |
Systemic Lupus Erythematosus | 7.5 | 3 | 1.5 |
Tic Disorder | 2 | 2.5 | -0.25 |
Tourette syndrome | 0.5 | -0.5 | |
Type 1 Diabetes | 6.5 | 4 | 0.63 |
Type 2 Diabetes | 13.5 | 10.8 | 0.25 |
Ulcerative colitis | 5 | 8 | -0.6 |
Unhealthy Ageing | 10.5 | 3 | 2.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.